Joshua Fitch is an editor for Contemporary Pediatrics.
Nirsevimab recommended by FDA Advisory Committee to prevent RSV in infantsJune 9th 2023
In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.
Medicaid-enrolled children not receiving mental health services after firearm injuriesJune 8th 2023
Investigators state public health strategies should prioritize early detection of mental health needs and equitable access to it, as some Medicaid-enrolled children are not receiving mental health services following a firearm injury.
FDA warns of drug compounding amid shortages of drugs containing semaglutideJune 7th 2023
Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.
Early risk factors associated with behavioral dysregulation trajectoriesJune 2nd 2023
Risk detection practices and targeted interventions promoting adaptive developmental trajectories for at-risk children can be successful by identifying the earliest antecedents of persisting emotional and behavioral dysregulation.
Getting children's mental health on trackMay 31st 2023
In this Contemporary Pediatrics® interview, Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California, details the rise in pediatric mental health concerns, emergency department visits, and the potentially concerning aspects of social media among youth.
How AI can help detect and monitor coughing in infants and young childrenMay 31st 2023
Devan Jaganath, MD, MPH, pediatric infectious disease physician, University of California San Francisco Benioff Children's Hospitals, explains how Hyfe AI and other artificial intelligence algorithms can detect and monitor coughing, potentially playing a role in treating RSV patients.
Here’s what parents think of pre-owned child health and safety equipmentMay 25th 2023
Over 50% of parents said they have used pre-owned child health and safety equipment. Whether it comes from family or a stranger, from cribs to car seats, all equipment should be inspected and researched before allowing a child to use it according to a C.S. Mott Children’s Hospital National Poll on Children’s Health.
FDA clears algorithm-based automated insulin dosing system for T1D patients 6 years and upMay 25th 2023
The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.
Government aims to streamline Medicaid billing for students with disabilities, expand health care services in schoolsMay 24th 2023
The US Department of Education, US Department of Health and Human Services, and the Biden-Harris Administration look to increase access to school-based health services, including mental health services, amid the national crisis.
Surgeon General issues advisory regarding effects social media has on youths’ mental healthMay 24th 2023
Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.
FDA approves adalimumab-adbm autoinjector pen for JIA, Crohn’s diseaseMay 22nd 2023
Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.
How FDA-approved B-VEC will help children with dystrophic epidermolysis bullosaMay 20th 2023
Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and olderMay 19th 2023
The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's supportMay 19th 2023
The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.
Early screening can play a critical role in pediatric mental healthMay 17th 2023
Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric ADMay 16th 2023
The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
Glucose levels are in target range at higher percentage with hybrid closed-loop systemMay 16th 2023
A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
What questions do pediatricians need to be prepared for as the federal COVID-19 PHE expires?May 11th 2023
Contemporary Pediatrics® Editorial Advisory Board member Andrew Schuman, MD, clinical assistant professor of pediatrics, Geisel School of Medicine, Dartmouth, shares some questions pediatricians can expect from parents as the federal COVID-19 public health emergency (PHE) expires.
Tina Tan, MD, discusses cost burden associated with the COVID-19 public health emergency expirationMay 11th 2023
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief, Contemporary Pediatrics®, discusses how the cost burden of the federal COVID-19 public health emergency (PHE) expiration on May 11, 2023, can impact testing and vaccination rates among children.